Abstract
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
Highlights
Methotrexate (MTX) is an efficacious drug in juvenile idiopathic arthritis (JIA)
If JIA patients are unresponsive to MTX, effective combination treatment with biologicals is required to prevent joint damage
Aim To develop a prediction model to identify MTX nonresponders according to the American College of Rheumatology 70 criteria during the first year of treatment
Summary
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. EH Pieter Van Dijkhuizen1*, Maja Bulatović, Marloes W Heijstek, Nico M Wulffraat, Saskia MF Pluijm, Robert de Jonge. From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. 14-18 September 2011
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
